» Articles » PMID: 20940405

The Myc-miR-17~92 Axis Blunts TGF{beta} Signaling and Production of Multiple TGF{beta}-dependent Antiangiogenic Factors

Overview
Journal Cancer Res
Specialty Oncology
Date 2010 Oct 14
PMID 20940405
Citations 151
Authors
Affiliations
Soon will be listed here.
Abstract

c-Myc stimulates angiogenesis in tumors through mechanisms that remain incompletely understood. Recent work indicates that c-Myc upregulates the miR-17∼92 microRNA cluster and downregulates the angiogenesis inhibitor thrombospondin-1, along with other members of the thrombospondin type 1 repeat superfamily. Here, we show that downregulation of the thrombospondin type 1 repeat protein clusterin in cells overexpressing c-Myc and miR-17∼92 promotes angiogenesis and tumor growth. However, clusterin downregulation by miR-17∼92 is indirect. It occurs as a result of reduced transforming growth factor-β (TGFβ) signaling caused by targeting of several regulatory components in this signaling pathway. Specifically, miR-17-5p and miR-20 reduce the expression of the type II TGFβ receptor and miR-18 limits the expression of Smad4. Supporting these results, in human cancer cell lines, levels of the miR-17∼92 primary transcript MIR17HG negatively correlate with those of many TGFβ-induced genes that are not direct targets of miR-17∼92 (e.g., clusterin and angiopoietin-like 4). Furthermore, enforced expression of miR-17∼92 in MIR17HG(low) cell lines (e.g., glioblastoma) results in impaired gene activation by TGFβ. Together, our results define a pathway in which c-Myc activation of miR-17∼92 attenuates the TGFβ signaling pathway to shut down clusterin expression, thereby stimulating angiogenesis and tumor cell growth.

Citing Articles

The lncRNA MIR181A1HG in extracellular vesicles derived from highly metastatic colorectal cancer cells promotes liver metastasis by remodeling the extracellular matrix and recruiting myeloid-derived suppressor cells.

Gu Y, Mi Y, Cao Y, Yu K, Zhang Z, Lian P Cell Biosci. 2025; 15(1):23.

PMID: 39972363 PMC: 11841002. DOI: 10.1186/s13578-025-01365-2.


A miRNA-Based Approach in Autosomal Dominant Polycystic Kidney Disease: Challenges and Insights from Adult to Pediatric Evidence.

Vitulano C, Forcina G, Colosimo S, Frattolillo V, Villani A, Marzuillo P Mol Diagn Ther. 2025; 29(2):183-193.

PMID: 39820940 DOI: 10.1007/s40291-024-00761-7.


MiRNAs as major players in brain health and disease: current knowledge and future perspectives.

Kapplingattu S, Bhattacharya S, Adlakha Y Cell Death Discov. 2025; 11(1):7.

PMID: 39805813 PMC: 11729916. DOI: 10.1038/s41420-024-02283-x.


Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges.

Seyhan A Int J Mol Sci. 2024; 25(14).

PMID: 39063215 PMC: 11277426. DOI: 10.3390/ijms25147974.


Dysregulation of exosomal miRNAs and their related genes in head and neck cancer patients.

Rizwan M, Mahjabeen I, Ashraf N, Arshad M, Haris M, Kayani M Future Oncol. 2024; 20(21):1479-1493.

PMID: 38861304 PMC: 11441060. DOI: 10.1080/14796694.2024.2351355.


References
1.
Lin C, Jackson A, Guo J, Linsley P, Eisenman R . Myc-regulated microRNAs attenuate embryonic stem cell differentiation. EMBO J. 2009; 28(20):3157-70. PMC: 2744176. DOI: 10.1038/emboj.2009.254. View

2.
Petrocca F, Vecchione A, Croce C . Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res. 2008; 68(20):8191-4. DOI: 10.1158/0008-5472.CAN-08-1768. View

3.
Xiao C, Srinivasan L, Calado D, Patterson H, Zhang B, Wang J . Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008; 9(4):405-14. PMC: 2533767. DOI: 10.1038/ni1575. View

4.
Warner B, Blain S, Seoane J, Massague J . Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway. Mol Cell Biol. 1999; 19(9):5913-22. PMC: 84444. DOI: 10.1128/MCB.19.9.5913. View

5.
Hunter C, Yu D, Gee M, Ngo C, Sevignani C, Goldschmidt M . Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J Immunol. 2001; 166(10):5878-81. DOI: 10.4049/jimmunol.166.10.5878. View